July 6, 2026 Uncategorized BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1 Read More
June 25, 2026 Uncategorized BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1 Read More
June 22, 2026 Uncategorized BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing Read More
June 15, 2026 Uncategorized BetterLife Pharma Announces Intent to Complete CAD $2 Million in Convertible Debenture to Complete BETR-001 IND Filing Read More
May 13, 2026 Uncategorized BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director Read More
April 10, 2026 Uncategorized BetterLife Pharma Announces Issuance of Shares and Extension of Convertible Debentures Read More
